🇺🇸 glargine insulin in United States

233 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Nausea — 29 reports (12.45%)
  2. Blood Glucose Increased — 27 reports (11.59%)
  3. Renal Failure Acute — 25 reports (10.73%)
  4. Diarrhoea — 24 reports (10.3%)
  5. Vomiting — 24 reports (10.3%)
  6. Drug Interaction — 22 reports (9.44%)
  7. Fall — 22 reports (9.44%)
  8. Hypoglycaemia — 22 reports (9.44%)
  9. Anaemia — 19 reports (8.15%)
  10. Dehydration — 19 reports (8.15%)

Source database →

glargine insulin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is glargine insulin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for glargine insulin in United States?

Baylor College of Medicine is the originator. The local marketing authorisation holder may differ — check the official source linked above.